Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapyPAP · pulmonary arterial hypertension1 finding from 1 reviewPhosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 387 participantsHigh
Group 1 Pulmonary arterial hypertension ‐ PDE5i vs ERAPAP · pulmonary arterial hypertension1 finding from 1 reviewPhosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes onlyno estimate extracted1 study · 11 participantsLow
Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placeboPAP · pulmonary arterial hypertension1 finding from 1 reviewPhosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes onlyno estimate extracted6 studies · 453 participantsModerate